Current Report Filing (8-k)
November 06 2017 - 5:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 29, 2017
RICH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
NEVADA
|
|
000-54767
|
|
46-3259117
|
(State
or other jurisdiction of
incorporation or organization)
|
|
Commission
file number
|
|
(IRS
Employer
Identification
No.)
|
9595
Wilshire Blvd, Suite 900
Beverly
Hills, CA 90212
(Address
of principal executive offices)
(424)
230-7001
(Registrant’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
◻
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
◻
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
◻
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
◻
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 4.01
|
Changes In Registrant’s Certifying Public Accountant
|
|
(a)
|
Dismissal of Anton & Chia, LLP (“Anton & Chia”)
|
On October 29, 2017 (the “Dismissal Date”),
the Board of Directors of the Company determined to dismiss Anton Chia as its independent registered public accounting firm.
Anton Chia has not prepared any reports on
the audited financial statements of the Company.
During the period commencing with
the engagement of Anton Chia on September 5, 2017 and through the Dismissal Date, there were no disagreements (as defined in
Item 304 of Regulation S-K) with Anton Chia on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Anton Chia, would have
caused it to make reference in connection with its opinion to the subject matter of the disagreement. Further, during
the period commencing with the engagement of Anton Chia on September 5, 2017 and through the Dismissal Date, there were no
reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).
The Company provided Anton Chia with a copy
of this Report prior to its filing with the Securities and Exchange Commission (the “SEC”) and requested Anton Chia
to furnish the Company with a letter addressed to the SEC, stating whether or not it agrees with the statements made above and,
if not, stating the respects in which they do not agree. A copy of such letter will be filed by amendment once it is
received.
|
(b)
|
Engagement of Fruci & Associates II, PLLC (“Fruci”)
|
On October 31, 2017 (the “Engagement
Date”), the Company’s Board of Directors approved the appointment of Fruci as the Company’s independent registered
public accounting firm. During the Company’s two most recent fiscal years, the subsequent interim periods thereto, and through
the Engagement Date, neither the Company nor anyone on its behalf consulted Fruci regarding either (1) the application of accounting
principles to a specified transaction regarding the Company, either completed or proposed, or the type of audit opinion that might
be rendered on the Company’s financial statements; or (2) any matter regarding the Company that was either the subject of
a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions to Item 304 of Regulation S-K) or a
reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
The exhibits listed in the following Exhibit Index are filed as
part of this Current Report on Form 8-K.
Exhibit
No.
|
Description
|
17
|
Letter regarding change in certifying accountant
(to be filed by amendment)
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
RICH
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
Dated:
October 20, 2017
|
|
|
|
By:
|
|
/s/ Ben
Chang
|
|
|
|
|
|
|
|
|
Ben
Chang
Chief
Executive Officer
|